Shaanxi Meibang Pharmaceutical Group Co., Ltd. (605033.SS)
CNY 12.67
(-0.63%)
CNY 12.67
(-0.63%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -480.17 Million CNY | -125.77% |
| 2022 | -212.67 Million CNY | 6.45% |
| 2021 | -227.33 Million CNY | -62.95% |
| 2020 | -139.51 Million CNY | 16.81% |
| 2019 | -167.69 Million CNY | -287.61% |
| 2018 | -43.26 Million CNY | -847.42% |
| 2017 | 5.78 Million CNY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -19.71 Million CNY | 91.23% |
| 2024 Q3 | -279.52 Million CNY | -1076.72% |
| 2024 Q1 | -224.86 Million CNY | 53.17% |
| 2023 Q4 | -480.17 Million CNY | -124.84% |
| 2023 FY | -480.17 Million CNY | -125.77% |
| 2023 Q3 | -213.56 Million CNY | -28.69% |
| 2023 Q2 | -165.95 Million CNY | 34.33% |
| 2023 Q1 | -252.71 Million CNY | -18.82% |
| 2022 Q3 | -298.95 Million CNY | -38.05% |
| 2022 Q2 | -216.55 Million CNY | -87.81% |
| 2022 Q1 | -115.3 Million CNY | 49.28% |
| 2022 FY | -212.67 Million CNY | 6.45% |
| 2022 Q4 | -212.67 Million CNY | 28.86% |
| 2021 Q4 | -227.33 Million CNY | 16.51% |
| 2021 Q3 | -272.27 Million CNY | -5220.13% |
| 2021 Q2 | -5.11 Million CNY | 93.96% |
| 2021 FY | -227.33 Million CNY | -62.95% |
| 2021 Q1 | -84.78 Million CNY | 57.48% |
| 2020 FY | -139.51 Million CNY | 16.81% |
| 2020 Q1 | 219.73 Million CNY | 0.0% |
| 2020 Q4 | -199.41 Million CNY | 0.0% |
| 2020 Q2 | -63.96 Million CNY | -129.11% |
| 2019 FY | -167.69 Million CNY | -287.61% |
| 2018 FY | -43.26 Million CNY | -847.42% |
| 2017 FY | 5.78 Million CNY | 0.0% |